产品参数
品 名 货 号 CAS 号 纯度( ≥) 规 格 价格 Trastuzumab PHM220221 180288-69-1 99.80% 1 mg ¥1600 5 mg ¥5500
品 名
货 号
CAS 号
纯度( ≥)
规 格
价格
Trastuzumab
PHM220221
180288-69-1
99.80%
1 mg
¥1600
5 mg
¥5500
产品简介
Trastuzumab 是一种人源化单克隆抗体,其以高亲和力与 HER2 选择性结合。
Trastuzumab 可用于 HER2 阳性转移性乳腺癌和 HER2 阳性胃癌的研究。
详细介绍
生物活性 Trastuzumab is a humanized monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research. IC50 & Target HER2 体外研究 (In Vitro) Treatment of HER2-overexpressing breast cancer cell lines with Trastuzumab results in induction of p27KIP1 and the Rb-related protein, p130, which in turn significantly reduces the number of cells undergoing S-phase. A number of other phenotypic changes are observed in vitro as a consequence of.Trastuzumab binding to HER2-overexpressing cells. Interaction of Trastuzumab with the human immune system via its human immunoglobulin G1 Fc domain may potentiate its antitumor activities. in vitro studies demonstrate that Trastuzumab is very effective in mediating antibody-dependent cell-mediated cytotoxicity against HER2-overexpressing tumor targets. Trastuzumab consists of two antigen-specific sites that bind to the juxtamembrane portion of the extracellular domain of the HER2 receptor and that prevent the activation of its intracellular tyrosine kinase. Trastuzumab recruits immune effector cells that are responsible for antibody-dependent cytotoxicity. The presence of Trastuzumab IgG significantly increases killing of all breast cancer cell lines. The ADCC activity of PBMCs evoked by Trastuzumab is equally strong against Trastuzumab-sensitive (SKBR-3) or Trastuzumab-resistant (JIMT-1) breast cancer cells, with dose-dependent cell death reaching 50–60% killing at an effector/target ratio of 60:1. MCE has not independently confirmed the accuracy of these methods. They are for reference only. 体内研究 (In Vivo) Trastuzumab treatment of mouse xenograft models results in marked suppression of tumor growth. When given in combination with standard cytotoxic chemotherapeutic agents, Trastuzumab treatment generally results in statistically superior antitumor efficacy compared with either agent given alone. Trastuzumab causes a significant growth inhibition of the outgrowth of macroscopic JIMT-1 xenograft tumors in both nude and SCID mice. MCE has not independently confirmed the accuracy of these methods. They are for reference only. 分子量 145531.50 Formula C6470H10012N1726O2013S42 CAS 号 180288-69-1 中文名称 曲妥珠单抗;曲妥单抗;群司珠单抗
生物活性
Trastuzumab is a humanized monoclonal antibody for patients with invasive breast cancers that
overexpress HER2. Trastuzumab has the potential for HER2 Positive Metastatic Breast Cancer
and HER2 Positive Gastric Cancer research.
IC50 & Target
HER2
体外研究 (In Vitro)
Treatment of HER2-overexpressing breast cancer cell lines with Trastuzumab results in induction
of p27KIP1 and the Rb-related protein, p130, which in turn significantly reduces the number of
cells undergoing S-phase. A number of other phenotypic changes are observed in vitro as a
consequence of.Trastuzumab binding to HER2-overexpressing cells. Interaction of Trastuzumab
with the human immune system via its human immunoglobulin G1 Fc domain may potentiate its
antitumor activities. in vitro studies demonstrate that Trastuzumab is very effective in
mediating antibody-dependent cell-mediated cytotoxicity against HER2-overexpressing tumor
targets. Trastuzumab consists of two antigen-specific sites that bind to the juxtamembrane portion
of the extracellular domain of the HER2 receptor and that prevent the activation of its intracellular
tyrosine kinase. Trastuzumab recruits immune effector cells that are responsible for
antibody-dependent cytotoxicity. The presence of Trastuzumab IgG significantly increases killing
of all breast cancer cell lines. The ADCC activity of PBMCs evoked by Trastuzumab is equally
strong against Trastuzumab-sensitive (SKBR-3) or Trastuzumab-resistant (JIMT-1) breast cancer
cells, with dose-dependent cell death reaching 50–60% killing at an effector/target ratio of 60:1.
MCE has not independently confirmed the accuracy of these methods. They are for
reference only.
体内研究 (In Vivo)
Trastuzumab treatment of mouse xenograft models results in marked suppression of tumor growth.
When given in combination with standard cytotoxic chemotherapeutic agents,
Trastuzumab treatment generally results in statistically superior antitumor efficacy compared with
either agent given alone. Trastuzumab causes a significant growth inhibition of the outgrowth of
macroscopic JIMT-1 xenograft tumors in both nude and SCID mice.
分子量
145531.50
Formula
C6470H10012N1726O2013S42
中文名称
曲妥珠单抗;曲妥单抗;群司珠单抗
销售电话:4006-169-114 技术咨询:020-32290876 客服电话:020-84224925 Email:whiga22@126.com 生产地址:广州国际生物岛螺旋四路1号研发A区第三层302房
粤公网安备 44011202000535号